dengue, dengue vaccine, dengue vaccine trial, dengue jab, DengiAll, National Institutes of Health, National Institute of Virology, Indian express

The trial will be conducted at 19 sites across 18 states and Union Territories. It will follow 10,335 healthy adults for a period of two years. The trial is primarily funded by the Indian Council of Medical Research, with the company partially bearing the expenses.

Written by Anonna Dutt

New Delhi | Updated: August 15, 2024 06:14 AM IST

3 min read

Dengue vaccine: Phase-3 of trial begins in Rohtak

DengiAll vaccine by Panacea Biotech works against all 4 dengue serotypes

The first phase III clinical trial for dengue vaccine in India was kickstarted on Wednesday, with the first person receiving a shot at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak.

The vaccine called DengiAll, which works against all four serotypes of dengue, has been developed by Panacea Biotech.

“The initiation of this Phase 3 clinical trial for India’s first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India’s capabilities in vaccine research and development,” Union Health Minister JP Nadda said.

Panacea’s vaccine uses live, weakened versions of all four dengue serotypes. These weakened versions of the virus were developed by the National Institute of Allergy and Infectious Diseases in the US— they deleted parts of the genetic code of DENV1, DENV3, and DENV4 and then genetically engineered a DENV2 backbone using parts from the weakened DENV 4, on which the others were tacked.

One of the biggest challenges with developing a dengue vaccine is that the four serotypes of the infection offer very little protection against each other, meaning one individual can be infected repeatedly with different serotypes. More importantly, it can lead to antibody dependent enhancement (ADE) — a person with low levels of antibodies against one serotype of dengue, getting a more severe infection with another serotype.

ADE was the reason for controversy surrounding the first dengue vaccine in the world. Only after a vaccination programme had been rolled out in the Philippines was it found that the vaccine could actually increase the risk of severe disease in the people who had not been infected before.

Story continues below this ad

The Serum Institute of India has used the same weakened virus from the United States to develop another vaccine candidate that has completed initial phases of trial. The company will conduct a large phase III trial in collaboration with ICMR in children between the ages of 2 and 18 years.

The same technology has also been used by Indian Immunologicals Limited to develop a vaccine that is undergoing initial phases of human trials. Hyderabad-based vaccine manufacturer BiologicalE has partnered with the global pharmaceutical company Takeda to produce its dengue vaccine, which is based on the same principle as the NIAID vaccine.

Anonna Dutt

Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government’s management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country’s space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University’s Dart Centre. Dutt has a Bachelor’s Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More

📣 For more lifestyle news, click here to join our WhatsApp Channel and also follow us on Instagram

Tags:

dengue

Dengue vaccine: Phase-3 of trial begins in Rohtak

The trial will be conducted at 19 sites across 18 states and Union Territories. It will follow 10,335 healthy adults for a period of two years. The trial is primarily funded by the Indian Council of Medical Research, with the company partially bearing the expenses.